Ozempic vision loss NAION lawsuit claims are growing rapidly as patients discover a link between their semaglutide medications and sudden, permanent eye damage. Non-arteritic anterior ischemic optic neuropathy (NAION) is essentially a stroke of the optic nerve. It cuts blood flow to the nerve that carries visual signals from your eye to your brain. The damage is often irreversible. If you took Ozempic, Wegovy, or Rybelsus and experienced sudden vision loss, you are not alone. Thousands of patients are now seeking answers through the legal system.
Understanding Ozempic Vision Loss NAION Lawsuit: Who Is at Risk
NAION strikes without warning. Patients typically wake up one morning with painless vision loss in one eye. The condition causes permanent damage to the optic nerve within hours. A landmark 2024 study published in JAMA Ophthalmology found alarming results. Patients with Type 2 diabetes taking semaglutide had more than four times the risk of developing NAION. Overweight patients using semaglutide for weight loss faced more than seven times the normal risk.
The median time from starting semaglutide to developing NAION is approximately 186 days. That means most cases appear within the first year of treatment. Risk factors that increase your vulnerability include older age, male sex, prolonged diabetes duration, elevated HbA1c levels, existing diabetic retinopathy, and obesity. Patients with a smaller optic disc (sometimes called a “disc at risk”) face heightened danger.
Novo Nordisk, the manufacturer of Ozempic and Wegovy, did not warn patients about this risk on drug labels. The Ozempic vision loss NAION lawsuit claims allege the company knew or should have known about this association. The World Health Organization concluded in June 2025 that semaglutide labeling should be revised to include NAION as a potential risk. The European Medicines Agency began a formal review in January 2025.
Active Lawsuits and MDL Status
The Judicial Panel on Multidistrict Litigation created a dedicated MDL for these vision loss claims on December 15, 2025. MDL No. 3163 consolidates all federal Ozempic vision loss NAION lawsuit cases into one court. U.S. District Judge Karen S. Marston in the Eastern District of Pennsylvania oversees the litigation. As of May 2026, approximately 86 cases are pending in this NAION-specific MDL.
A separate MDL (No. 3094) handles gastrointestinal injury claims from GLP-1 drugs. That litigation has over 3,600 pending cases. Both MDLs are before Judge Marston. In March 2026, the court appointed a plaintiffs’ leadership team to organize the NAION cases. Science Day is scheduled for June 2, 2026. Attorneys will present medical evidence linking GLP-1 drugs to optic nerve damage.
| MDL Number | Injury Type | Court | Judge | Cases Pending | Status |
|---|---|---|---|---|---|
| MDL 3163 | NAION / Vision Loss | E.D. Pennsylvania | Karen S. Marston | ~86 | Science Day June 2026 |
| MDL 3094 | Gastroparesis / GI Injuries | E.D. Pennsylvania | Karen S. Marston | ~3,636 | Active discovery |
New Ozempic vision loss NAION lawsuit filings continue each month. Attorneys are still accepting cases. No global settlement has been reached as of May 2026. The litigation remains in its early stages. Bellwether trial selection has not yet occurred.
Eligibility and Evidence Requirements
You may qualify for an Ozempic vision loss NAION lawsuit if you meet three core criteria. First, you took a semaglutide medication (Ozempic, Wegovy, or Rybelsus). Second, you developed NAION or experienced sudden vision loss. Third, your eye condition appeared during or after your use of the medication. You must also file within your state’s statute of limitations, typically two to three years from diagnosis or discovery of the drug connection.
Documentation is critical. You need pharmacy records proving you received semaglutide prescriptions. Medical records showing your NAION diagnosis are essential. Ophthalmology reports, visual field tests, and OCT scans strengthen your claim. Hospital emergency room records from the initial vision loss event are especially valuable. You cannot file based on memory alone. Written proof of both medication use and diagnosis is required.
Even if your vision partially recovered, you may still qualify. The Ozempic vision loss NAION lawsuit covers pain and suffering, medical expenses, lost wages, and diminished quality of life. Patients who lost vision in one eye still have strong claims. Those who experienced vision loss in both eyes may have claims for higher damages. A licensed attorney can evaluate your specific situation and advise you on the strength of your case.
Step-by-Step: How to Check If You Qualify
Step 1: Confirm your medication history. Contact your pharmacy and request a complete prescription history for any GLP-1 receptor agonist drug. This includes Ozempic, Wegovy, Rybelsus, and generic semaglutide. Note the start date, dosage changes, and duration of use.
Step 2: Gather your eye medical records. Request records from your ophthalmologist or neuro-ophthalmologist. You need documentation of your NAION diagnosis, including the date symptoms began. Visual field test results and optical coherence tomography (OCT) scans are important. Ask for any notes connecting your vision loss timeline to your medication use.
Step 3: Consult a mass tort attorney experienced with Ozempic vision loss NAION lawsuit cases. Most offer free case evaluations. Share your medication timeline and medical records. The attorney will assess whether your case fits the MDL criteria. They can determine if the timing and medical evidence support a causal connection. Do not delay. Statutes of limitations vary by state and may bar your claim if you wait too long.
Financial Considerations and Timeline
Mass tort attorneys handling Ozempic vision loss NAION lawsuit claims typically work on a contingency fee basis. This means you pay nothing upfront. The attorney advances all costs and only collects a percentage if you receive compensation. Contingency fees typically range from 33% to 40% of any recovery. Always confirm the fee structure in writing before signing a retainer agreement.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Timeline expectations should be realistic. MDL litigation moves slowly. Science Day is June 2026. Bellwether trials likely will not begin until 2027 or later. If settlements occur, they could take two to four years from today. Individual state court cases may resolve faster. Your attorney can advise whether federal MDL or state court filing makes more sense for your situation.
Potential compensation in Ozempic vision loss NAION lawsuit cases may cover medical bills, future treatment costs, lost income, and pain and suffering. Vision loss profoundly impacts daily life. Patients lose the ability to drive, work, and perform routine activities. These non-economic damages often represent the largest portion of recovery. No settlement values have been established yet because the litigation is still in early stages.
Finding the Right Attorney
Look for an attorney with specific experience in pharmaceutical mass tort litigation. Ask whether they have handled GLP-1 or vision loss cases before. Check if they are involved in MDL 3163 or have relationships with the plaintiffs’ leadership committee. An experienced attorney understands the medical evidence linking semaglutide to NAION.
Ask direct questions during your consultation. How many Ozempic vision loss NAION lawsuit cases does the firm currently handle? What is their communication policy? Will you work with the lead attorney or a case manager? Do they advance all litigation costs? A good firm will answer these questions openly and without pressure.
You should consult a licensed attorney as soon as possible. The Ozempic vision loss NAION lawsuit filing deadline depends on your state’s statute of limitations. Some states allow only two years from the date of injury or discovery. An attorney can determine your deadline and protect your right to file. Most consultations are free and carry no obligation. You deserve answers about what happened to your vision and whether you may qualify for compensation.
Frequently Asked Questions
What is NAION and how does it relate to Ozempic?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It is a sudden loss of blood flow to the optic nerve, sometimes called an “eye stroke.” A 2024 JAMA Ophthalmology study found that semaglutide users face four to seven times higher risk of developing NAION. The Ozempic vision loss NAION lawsuit alleges Novo Nordisk failed to warn patients about this serious risk. Damage from NAION is typically permanent and cannot be reversed with treatment.
Can I file a lawsuit if my vision partially recovered?
Yes. Partial recovery does not disqualify you from the Ozempic vision loss NAION lawsuit. Any documented vision loss, visual field defect, or optic nerve damage during or after semaglutide use may support a claim. Compensation covers medical expenses, pain and suffering, and impact on quality of life. Even temporary vision loss causes significant distress and medical costs. Consult an attorney to evaluate your specific circumstances.
How long do I have to file a claim?
Statutes of limitations vary by state, ranging from two to four years. The clock typically starts when you received your NAION diagnosis or when you discovered the connection to your medication. Because the Ozempic vision loss NAION lawsuit MDL was only created in December 2025, many patients still have time to file. However, waiting too long risks losing your right to seek compensation. Contact a mass tort attorney promptly for a free deadline assessment.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- New York Tort Reform Guide
- Pennsylvania Tort Reform Guide
- Florida Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.